BioAdaptives, Inc. Announces Institutional Review Board Approval of a Human Clinical Trial for Zeranovia™

Rhea-AI Summary

BioAdaptives (OTC: BDPT) has received Institutional Review Board approval for a human clinical trial of Zeranovia™, its weight management product. The trial will be conducted in Las Vegas, Nevada, with the first phase focusing on dosing confirmation and side effect monitoring. The initial participant positions were quickly filled through website sign-ups. Zeranovia™ is based on a high-protein blend with vitamins, minerals, and five herbal supplements, including four adaptogens. The company aims to demonstrate results comparable to synthetic GLP-1 and GIP treatments. According to NIH's Office of Dietary Supplements, less than 1.0% of nutraceuticals in the US undergo human clinical trials.

Positive

• Received IRB approval for human clinical trial of weight management product
• Strong initial response with quick filling of first trial phase positions
• Product potentially competing with established GLP-1 and GIP treatments

Negative

• Product still in early clinical trial phase with unproven efficacy
• Multiple trial phases required before potential commercialization

LAS VEGAS, Nov. 25, 2024 (GLOBE NEWSWIRE) -- via IBN – BioAdaptives Inc. (OTC: BDPT) received approval today for a human clinical trial of its weight management product, Zeranovia™.

The trial, approved by an Institutional Review Board, will be managed and supervised by doctors in Las Vegas, Nevada. Sign-ups to participate in the clinical trial have been available on Zeranovia’s website. An excellent response from interested participants quickly filled available positions for the first trial stage. The first phase is designed to confirm dosing and determine if any new side effects are revealed. The next stage of the trial will be open to additional participants.

BioAdaptives™ CEO James Keener stated: “According to data from the National Institutes of Health's Office of Dietary Supplements (ODS), less than 1.0% of nutraceuticals sold in the United States undergo examination in human clinical trials.”

Keener continued: “We are committed to supplying the highest quality products with provable scientific results. Zeranovia’s™ success is based on a high-protein blend of vitamins, minerals, and five concentrated herbal supplements, four of which are adaptogens.”

Before moving Zeranovia™ to BioAdaptives™, Keener’s team spent almost one year in product development, including extensive lab work. Based on those efforts and the knowledge obtained, human clinical trials are expected to mirror the results already achieved. If so, this will be the first natural product that compares favorably to the synthetic medical treatments of GLP-1 and GIP.

To learn more, please visit: Zeranovia.com

About BioAdaptives, Inc.
BioAdaptives, Inc. (OTC: BDPT) is a leader in the nutritional products industry, committed to delivering innovative solutions that enhance quality of life, anti-aging, cell repair, and well-being. With a deep focus on research, customer insights, and sustainable practices, BioAdaptives Inc. redefines what customers can expect from nutritional products. For more information, visit www.bioadaptives.com.

Forward-Looking Statements:

This press release contains forward-looking statements, including those related to the anticipated performance and success of the new product line. These statements are subject to risks and uncertainties that could materially cause actual results to differ. Please refer to our filings with the Securities and Exchange Commission for more information on potential risks.

This launch is expected to further establish BioAdaptives, Inc. as an industry innovator dedicated to bringing scientifically advanced, market-aligned solutions to customers worldwide.

Contact:
Emily Harrison
Investor Relations
BioAdaptives, Inc.
(702) 659-8829
Info@bioadaptives.com

Wire Service Contact:
IBN
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com

FAQ

What is the purpose of BioAdaptives (BDPT) Zeranovia clinical trial?

The clinical trial aims to confirm dosing and identify potential side effects of Zeranovia, a weight management product, with the goal of comparing it to synthetic GLP-1 and GIP treatments.

When did BioAdaptives (BDPT) receive IRB approval for Zeranovia trials?

BioAdaptives received Institutional Review Board approval for Zeranovia human clinical trials on November 25, 2024.

What is the composition of BioAdaptives (BDPT) Zeranovia product?

Zeranovia is composed of a high-protein blend containing vitamins, minerals, and five herbal supplements, with four of them being adaptogens.

Where will BioAdaptives (BDPT) conduct the Zeranovia clinical trials?

The Zeranovia clinical trials will be managed and supervised by doctors in Las Vegas, Nevada.